

Title (en)

DAPSONE FORMULATIONS AND METHODS OF USING SAME

Title (de)

DAPSON-FORMULIERUNGEN UND VERFAHREN ZU DEREN VERWENDUNG

Title (fr)

FORMULATIONS DE DAPSONE ET LEURS PROCÉDÉS D'UTILISATION

Publication

EP 3911415 A1 20211124 (EN)

Application

EP 21742678 A 20210330

Priority

- US 202063001972 P 20200330
- US 202063029685 P 20200525
- CA 3083002 A 20200610
- CA 2021050425 W 20210330

Abstract (en)

[origin: WO2021195765A1] A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

IPC 8 full level

A61P 31/14 (2006.01)

CPC (source: EP)

A61K 9/0043 (2013.01); **A61K 9/0075** (2013.01); **A61K 9/10** (2013.01); **A61K 31/136** (2013.01); **A61K 31/16** (2013.01); **A61K 31/65** (2013.01); **A61K 31/7052** (2013.01); **A61K 47/10** (2013.01); **A61P 31/14** (2017.12)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2021195765 A1 20211007; EP 3911415 A1 20211124; EP 3911415 A4 20221012

DOCDB simple family (application)

CA 2021050425 W 20210330; EP 21742678 A 20210330